Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome
It still remains to be demonstrated that using molecular profiling to guide therapy improves patient outcome in oncology. Classification of somatic variants is not straightforward, rendering treatment decisions based on variants with unknown significance (VUS) hard to implement. The oncogenic activi...
Main Authors: | Maud Kamal, Gabi Tarcic, Sylvain Dureau, Oded Edelheit, Zohar Barbash, Charlotte Lecerf, Claire Morel, Benjamin Miron, Celine Callens, Nicolas Servant, Ivan Bieche, Michael Vidne, Christophe Le Tourneau |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-05-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12180 |
Similar Items
-
Identifying the genetic causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome sequencing (WES)
by: Gordon K C Leung, et al.
Published: (2018-10-01) -
Prevalence and oncologic outcomes of mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
by: Jun Hyeong Seo, et al.
Published: (2019-11-01) -
Gene mutations: Understanding the significance using in silico analysis
by: K Sanjana Pillay
Published: (2015-01-01) -
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
by: Istvan Petak, et al.
Published: (2021-06-01) -
Determination of the Pathological Features of NPC1 Variants in a Cellular Complementation Test
by: Xiao Feng, et al.
Published: (2019-10-01)